smin15 Jan 2013 22:12
Smiths Group (SMIN) looks ripe for a break-up. We've said so before, but the recession and a big deficit in its pension funds kept things quiet. Now that Invensys and others have shown these needn't be an obstacle, interest is swirling again. The fundamentals are attractive, too. So, even after a good run, shares in Smiths are worth buying.
Chief executive Philip Bowman admits Smiths is an eclectic mix. Yes, each division is profitable and diverse enough to lessen the chances of a share price shock, but, be in no doubt, Mr Bowman will sell at the right price. Pension issues scuppered the £2.45bn sale of the medical division two years ago, but, as Invensys showed last month, a pension-fund deficit no longer acts as a 'poison pill' to deter bidders.
By the end of July, low interest rates had tripled Smiths' pension deficit to £620m. But analysts at Deutsche Bank reckon Smiths may only have to stick an extra £370m into the pension fund to secure a sale of the medical division - hardly a deal-breaker. What's more, a rise in bond yields of a percentage point or so could wipe out the deficit, according to Nomura. A government review of pension fund accounting methods might even do the job.
Granted, selling the medical division, or the other big profit generator, John Crane, which supplies mechanical seals and bearings to oil companies, would still take some work. But Smiths could easily offload a smaller division. "Flex-Tek is an absolute gem and could be sold without ruffling any feathers," says Sandy Morris, an analyst at broker Jefferies.